Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors

BACKGROUND: Over 96% of high‐grade ovarian carcinomas and 50% of all cancers are characterized by alterations in the p53 gene. Therapeutic strategies to restore and/or reactivate the p53 pathway have been challenging. By contrast, p63, which shares many of the downstream targets and functions of p53...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunaratne, Preethi H., Pan, Yinghong, Rao, Abhi K., Lin, Chunru, Hernandez‐Herrera, Anadulce, Liang, Ke, Rait, Antonina S., Venkatanarayan, Avinashnarayan, Benham, Ashley L., Rubab, Farwah, Kim, Sang Soo, Rajapakshe, Kimal, Chan, Clara K., Mangala, Lingegowda S., Lopez‐Berestein, Gabriel, Sood, Anil K., Rowat, Amy C., Coarfa, Cristian, Pirollo, Kathleen F., Flores, Elsa R., Chang, Esther H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617807/
https://www.ncbi.nlm.nih.gov/pubmed/31012964
http://dx.doi.org/10.1002/cncr.32053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617807/
https://www.ncbi.nlm.nih.gov/pubmed/31012964
http://dx.doi.org/10.1002/cncr.32053

Ejemplares similares